Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy

医学 多药 糖尿病 低血糖 2型糖尿病 痴呆 药物治疗 二甲双胍 吡格列酮 糖尿病管理 重症监护医学 利拉鲁肽 内科学 内分泌学 疾病
作者
Miriam Longo,Giuseppe Bellastella,Maria Ida Maiorino,Juris J. Meier,Katherine Esposito,Dario Giugliano
出处
期刊:Frontiers in Endocrinology [Frontiers Media SA]
卷期号:10 被引量:145
标识
DOI:10.3389/fendo.2019.00045
摘要

Diabetes is becoming one of the most widespread health burning problems in the elderly. Worldwide prevalence of diabetes among subjects over 65 years was 123 million in 2017, a number that is expected to double in 2045. Old patients with diabetes have a higher risk of common geriatric syndromes, including frailty, cognitive impairment and dementia, urinary incontinence, traumatic falls and fractures, disability, side effects of polypharmacy, which have an important impact on quality of life and may interfere with anti-diabetic treatment. Because of all these factors, clinical management of type 2 diabetes in elderly patients currently represents a real challenge for the physician. Actually, the optimal glycemic target to achieve for elderly diabetic patients is still a matter of debate. The American Diabetes Association suggests a HbA1c goal 6.5%) for patients with concurrent serious illness and at high risk of hypoglycemia. By contrast, the American College of Physicians (ACP) suggests more conservative goals (HbA1c levels between 7% and 8%) for most older patients, and a less intense pharmacotherapy, when HbA1C levels are ≤ 6.5%. Management of glycemic goals and antihyperglycemic treatment has to be individualized in accordance to medical history and comorbidities, giving preference to drugs that are associated with low risk of hypoglycemia. Antihyperglycemic agents considered safe and effective for type 2 diabetic older patients include: metformin (the first-line agent), pioglitazone, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists. Insulin secretagogue agents have to be used with caution because of their significant hypoglycemic risk; if used, short-acting sulfonylureas, as gliclazide, or glinides as repaglinide, should be preferred. When using complex insulin regimen in old people with diabetes, attention should be paid for the risk of hypoglycemia. In this paper we aim to review and discuss the best glycemic targets as well as the best treatment choices for older people with type 2 diabetes based on current international guidelines.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
迷你的秋双完成签到,获得积分10
1秒前
猪猪hero发布了新的文献求助10
2秒前
2秒前
2秒前
瓶子完成签到 ,获得积分10
3秒前
默默的斓完成签到,获得积分20
3秒前
4秒前
Evina完成签到,获得积分10
4秒前
lin发布了新的文献求助10
4秒前
小蘑菇应助17793654973采纳,获得10
5秒前
5秒前
Lin_sandwich发布了新的文献求助20
5秒前
Hunter发布了新的文献求助10
5秒前
6秒前
kaiz完成签到,获得积分20
6秒前
6秒前
lang发布了新的文献求助10
6秒前
7秒前
Cc完成签到 ,获得积分10
7秒前
资山兰发布了新的文献求助100
7秒前
科研通AI6.3应助天阳采纳,获得10
7秒前
神明发布了新的文献求助10
7秒前
12Q发布了新的文献求助10
7秒前
可爱的函函应助学习采纳,获得10
8秒前
滔滔江水完成签到,获得积分10
8秒前
坦率惊蛰发布了新的文献求助10
8秒前
科研通AI6.1应助HHHH采纳,获得10
9秒前
11秒前
xxguge发布了新的文献求助10
12秒前
12秒前
许琦发布了新的文献求助10
13秒前
xiaobai完成签到,获得积分10
14秒前
柚子完成签到,获得积分10
14秒前
15秒前
许思真完成签到,获得积分10
15秒前
16秒前
xiyang完成签到 ,获得积分10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6019311
求助须知:如何正确求助?哪些是违规求助? 7613052
关于积分的说明 16161875
捐赠科研通 5167111
什么是DOI,文献DOI怎么找? 2765589
邀请新用户注册赠送积分活动 1747333
关于科研通互助平台的介绍 1635572